Bliss GVS Pharma Limited has informed the Exchange about change in Management
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The filing is a Board Meeting outcome dated May 12, 2026. Key highlights: (1) Audited standalone net profit of ₹3,242.25 lakh and consolidated net profit of ₹9,687.44 lakh for FY ended March 31, 2026 — strong growth driven by pharma exports and new subsidiary additions in Kenya and DRC; (2) Unmodified audit opinion issued by Kalyaniwalla & Mistry LLP on both standalone and consolidated results; (3) Board recommended a final dividend of ₹1 per share (100% payout) subject to shareholder approval at the 41st AGM on July 15, 2026; (4) Reappointed BDO India Services Private Limited as Internal Auditor for FY 2026-27; (5) During the year, the company incorporated two new step-down subsidiaries (Theralife Pharma Ltd in Kenya and Theralife Pharma RDC Private Limited in DRC). The headline reference to 'change in management' appears to be a mismatch — no management or director changes are mentioned in the document.
No management change was actually disclosed. The results reflect solid earnings growth and a shareholder-friendly dividend. The expansion into new geographies (Kenya, DRC) signals a positive strategic direction.